AbbVie Shares Up; Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study
January 14 2020 - 12:22PM
Dow Jones News
By Michael Dabaie
AbbVie Inc. (ABBV) shares were up about 1% to $88.16 around
midday.
The biopharmaceutical company said Skyrizi met the primary and
all ranked secondary endpoints, including superiority at week 52,
versus Cosentyx in a head-to-head Phase 3 study in adults with
moderate to severe plaque psoriasis.
Skyrizi showed significantly higher rates of skin clearance
compared with Cosentyx, meeting the primary endpoint of superiority
with at least a 90% improvement from baseline in the Psoriasis Area
and Severity Index at week 52, AbbVie said.
The safety profile of Skyrizi was consistent with that observed
in previously reported studies, with no new safety signals observed
through week 52, the company said. Skyrizi is part of a
collaboration between Boehringer Ingelheim and AbbVie, with AbbVie
leading development and commercialization globally.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 14, 2020 12:07 ET (17:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024